default author photo

Meng-Xia Zhang

Sun Yat-sen University (SYSU) - Sun Yat-Sen University Cancer Center

Guangzhou

China

  • Sun Yat-sen University (SYSU) - Sun Yat-Sen University Cancer Center

SCHOLARLY PAPERS

1

DOWNLOADS

31

TOTAL CITATIONS

0

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

Comprehensive Immune Landscape and Molecular Characteristics of Clinical Responses to Chemotherapy, Antiangiogenic Agents and PD-1 Inhibitors in Advanced Nasopharyngeal Cancer

Number of pages: 107 Posted: 10 Mar 2022
Rui You, Xiong Zou, Meng-Xia Zhang, Wei-Jing Zhang, Xi Ding, Xiao Wang, Han-Shi Xu, Yong-Long Liu, Yan-Feng Ouyang, Chong-Yang Duan, Chen-Mei Gu, Zhi-Qiang Wang, You-Ping Liu, Yi-Jun Hua, Pei Yu Huang and Ming-Yuan Chen
Sun Yat-sen University (SYSU) - State Key Laboratory of Oncology in South China, Sun Yat-sen University (SYSU) - State Key Laboratory of Oncology in South China, Sun Yat-sen University (SYSU) - Sun Yat-Sen University Cancer Center, Sun Yat-sen University (SYSU) - State Key Laboratory of Oncology in South China, Sun Yat-sen University (SYSU) - Department of Nasopharyngeal Carcinoma, Beijing Novogene Bioinformatics Technology Co., Ltd, Sun Yat-sen University (SYSU) - Sun Yat-Sen University Cancer Center, Sun Yat-sen University (SYSU) - State Key Laboratory of Oncology in South China, Sun Yat-sen University (SYSU) - State Key Laboratory of Oncology in South China, Sun Yat-sen University (SYSU) - State Key Laboratory of Oncology in South China, Sun Yat-sen University (SYSU) - Sun Yat-Sen University Cancer Center, Sun Yat-sen University (SYSU) - Sun Yat-Sen University Cancer Center, Sun Yat-sen University (SYSU) - State Key Laboratory of Oncology in South China, Sun Yat-sen University (SYSU) - State Key Laboratory of Oncology in South China, Sun Yat-sen University (SYSU) - State Key Laboratory of Oncology in South China and Sun Yat-sen University (SYSU) - Department of Nasopharyngeal Carcinoma
Downloads 31 (1,304,549)

Abstract:

Loading...

nasopharyngeal carcinoma, apatinib, toripalimab, gemcitabine, recurrent/metastatic, genomic, transcriptional analyses